îæ€çŽ¢
îæ€çŽ¢
î
Apimeds Pharmaceuticals US Inc
APUSîãŠã©ãããªã¹ãã«è¿œå
0.900USD
+0.005+0.58%
çµå€Â 07/02, 13:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
11.32Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
詳现ãã£ãŒãã衚瀺
TradingKey åŸè¡šIntraday
1m
30m
1h
D
W
M
D
æ¬æ¥
+0.58%
5æ¥é
0.00%
1ã¶æ
-36.17%
6ã¶æ
-45.95%
幎åæ¥
-45.12%
1幎é
-49.44%
äž»èŠããŒã¿
0.932å§å€
0.950é«å€
188.93Kåºæ¥é«
æ倱é¡çŽè¿12ã¶æPER
--äºæ³PER
--çŽè¿12ã¶æé
åœ
1.50%売買å転ç
0.885åæ¥çµå€
0.861å®å€
127.94K売買代é
æ倱é¡æ ªäŸ¡åçç
0.09PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-7.31%ç·è³ç£å©çç
4.03152é±é«å€
1.13åºæ¥é«æ¯ç%
-1.39MçŽå©ç
12.58Mæ ªåŒæ°
-0.55151æ ªåœããå©çïŒEPSïŒ
--ããŒã¿å€
-7.90%èªå·±è³æ¬å©çç
0.95152é±å®å€
10.07%æ¯ãå¹
--ç²å©çç
11.32Mæ䟡ç·é¡
-3.98ãªã¹ã¯ãªã¿ãŒã³
9.34%ãªã¹ã¯ç
TradingKey æ ªåŒã¹ã³ã¢
ããŒã¿ãäžååãªãããæ ªåŒã¹ã³ã¢ã¯å©çšã§ããŸããã
Apimeds Pharmaceuticals US Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
財åææšî
EPS
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Apimeds Pharmaceuticals US Incã®äŒæ¥æ å ±î
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
äŒæ¥ã³ãŒãAPUS
äŒæ¥åApimeds Pharmaceuticals US Inc
æé«çµå¶è²¬ä»»è
ãCEOãMenon (Vin)
ãŠã§ããµã€ãhttps://www.apimedsus.com/
é¢é£éèåå
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%人æ°éæ
52852.900
+10.400Â (+0.02%)
29669.900
+358.500Â (+1.22%)
7507.800
+36.300Â (+0.49%)
14963.000
+160.000Â (+1.08%)
69676.000
+1528.000Â (+2.24%)
6412.400
+59.600Â (+0.94%)
68.683
+0.339Â (+0.50%)
308.630
+14.250Â (+4.84%)
194.830
-2.750Â (-1.39%)
4174.610
+52.700Â (+1.28%)
ãããã質å
Apimeds Pharmaceuticals US IncïŒAPUSïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îApimeds Pharmaceuticals US IncïŒAPUSïŒã®çŸåšã®æ ªäŸ¡ã¯0.90ã§ãã
Apimeds Pharmaceuticals US Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îApimeds Pharmaceuticals US Incã®ãã£ãã«ãŒã·ã³ãã«ã¯APUSã§ãã
Apimeds Pharmaceuticals US Incã®52é±é«å€ã¯ãããã§ããïŒ
îApimeds Pharmaceuticals US Incã®52é±é«å€ã¯4.03ã§ãã
Apimeds Pharmaceuticals US Incã®52é±å®å€ã¯ãããã§ããïŒ
îApimeds Pharmaceuticals US Incã®52é±å®å€ã¯0.95ã§ãã
Apimeds Pharmaceuticals US Incã®æ䟡ç·é¡ã¯ãããã§ããïŒ
îApimeds Pharmaceuticals US Incã®æ䟡ç·é¡ã¯11.32Mã§ãã
Apimeds Pharmaceuticals US Inc (APUS) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îApimeds Pharmaceuticals US IncïŒAPUSïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-0.55ã§ãã